Room temperature stable MVA-GP pox vectored vaccine against CCHF

拟议方案的目标是实现一种室温稳定、可随时注射的克里米亚-刚果出血热(CCHF)疫苗。具有成功稳定活病毒和细菌载体记录的HydRIS(皮下再水化注射系统)稳定平台将被评估以稳定MVA-GP疫苗--一种由卫生保护局开发的新型基于痘载体的疫苗。该方案的成功完成将能够开发一种不依赖冷链分配的CCHF疫苗，这在世界上某些易受CCHF影响的地区尤其具有挑战性。作为一项平台技术，该方案将进一步展示对一系列MVA载体疫苗的适用性。Nova Biophma Technologies是Nova集团的一部分，继续开发尖端技术，并以其先进的临床和商业制造能力为支撑。PHE的存在是为了保护和改善国家的健康和福祉，并减少健康不平等。它通过世界级的科学、知识和情报、宣传、伙伴关系和提供专门的公共卫生服务来做到这一点。卫生与公众服务部是卫生部的一个业务自主的执行机构。PHE Porton从事了解传染病的基础和应用研究，拥有高度遏制病原体的专业知识。PHE Porton专门从事翻译研究，以开发和测试公共卫生干预措施，包括疫苗和诊断等新产品。

The objective of the proposed programme is to achieve a room-temperature stable, ready-to-inject vaccine against Crimean-Congo haemorrhagic fever (CCHF). HydRIS (Hypodermic Re-hydration Injection System) stabilisation platform with a proven track record of successfully stabilising live viral and bacterial vectors will be assessed to stabilise MVA-GP vaccine- a novel pox-vector based vaccine against CCHF developed by the Health Protection Agency. The successful completion of the programme will enable to develop a CCHF vaccine that will not rely on the cold-chain-distribution, which is especially challenging in certain parts of the world vulnerable to CCHF. As a platform technology, this programme will further demonstrate the applicability to a range of MVA-vectored vaccines. Nova Biopharma Technologies part of Nova Group continue to develop cutting edge technologies supported by it's advanced manufacturing capabilities for both clinical and commercial manufacturing scales. PHE exists to protect and improve the nation’s health and wellbeing, and reduce health inequalities. It does this through world-class science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. PHE is an operationally autonomous executive agency of the Department of Health. PHE Porton undertakes basic and applied research into understanding infectious diseases, with expertise in high containment pathogens. PHE Porton specialise in translational research to develop and test interventions for public health, including new products such as vaccines and diagnostics.